ArticleEuropean journal of medical research2026
Serum butyraldehyde levels are associated with abdominal aortic calcification: a population-based study.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAbdominal aortic calcification (AAC) is a strong predictor of cardiovascular morbidity but lacks effective interventions. Aldehydes, a diverse class of environmental and endogenous compounds, have been implicated in various chronic diseases, yet their individual and combined effects on vascular calcification remain unclear.
methodsThis study investigated associations between six serum aldehydes (benzaldehyde, butyraldehyde, heptanaldehyde, hexanaldehyde, isopentanaldehyde, propanaldehyde) and AAC in a nationally representative sample of US adults from the 2013-2014 NHANES. AAC was measured via lateral lumbar spine DXA, and serum aldehydes were quantified using gas chromatography-mass spectrometry. Analyses using weighted logistic regression and quantile g-computation (qgcomp) models, adjusted for demographic and metabolic confounders, revealed the associations between aldehydes and AAC.
resultsThis study included 1208 NHANES participants. Each log₂-unit increase in butyraldehyde concentration was associated with a 36.7% lower AAC risk (adjusted OR = 0.633, 95% CI 0.436-0.930), and individuals in the highest tertile of exposure had a 46% reduced risk compared to those in the lowest tertile. After FDR correction for multiple comparisons, butyraldehyde exhibited the strongest association with AAC among the aldehydes examined (FDR-adjusted p = 0.096). None of the other aldehydes showed significant associations with AAC in fully adjusted models. In the mixture analysis, butyraldehyde also demonstrated the strongest inverse association with AAC (β = -0.442). The inverse association between butyraldehyde and AAC was more pronounced in individuals with klotho deficiency.
conclusionThese findings indicate that butyraldehyde is inversely associated with AAC, not only highlighting its potential role in vascular calcification but also suggesting the necessity of aldehyde-specific assessments in cardiovascular risk assessment. Besides, butyraldehyde may serve as a promising candidate for therapeutic development in high-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.